Poziotinib Shows Promise In EGFR and HER2 EXON 20 Mutated Non-Small Cell Lung Cancer

Published by W Butcher on

Patients with epidermal growth factor receptor (EGFR) exon 20 mutant metastatic non-small cell lung cancer (NSCLC) showed clinical benefit and tolerable safety following treatment with poziotinib according to findings presented at the ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021 held on 1-2 March. Further study of poziotinib in patients with metastatic NSCLC and EGFR or HER2 exon 20 mutations showed that the safety profile could be improved by twice daily dosing.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.